2005
DOI: 10.1200/jco.2005.23.16_suppl.540
|View full text |Cite
|
Sign up to set email alerts
|

The treatment of pregnant women with breast cancer and the outcomes of the children exposed to chemotherapy in utero

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
4
0
1

Year Published

2006
2006
2021
2021

Publication Types

Select...
4
2

Relationship

0
6

Authors

Journals

citations
Cited by 8 publications
(5 citation statements)
references
References 0 publications
0
4
0
1
Order By: Relevance
“…19 The indications for systemic chemotherapy in the pregnant patient are similar to the nonpregnant breast cancer patients except that chemotherapy should not be given during the first trimester since this period has the greatest risk of fetal malformation. [20][21][22] The risks of fetal malformation in the second and third trimesters are approximately 1.3%, which is a rate similar to fetuses not exposed to chemotherapy. 23 Fetal monitoring prior to each chemotherapy cycle is recommended.…”
Section: Treatment Of Breast Cancer During Pregnancymentioning
confidence: 99%
“…19 The indications for systemic chemotherapy in the pregnant patient are similar to the nonpregnant breast cancer patients except that chemotherapy should not be given during the first trimester since this period has the greatest risk of fetal malformation. [20][21][22] The risks of fetal malformation in the second and third trimesters are approximately 1.3%, which is a rate similar to fetuses not exposed to chemotherapy. 23 Fetal monitoring prior to each chemotherapy cycle is recommended.…”
Section: Treatment Of Breast Cancer During Pregnancymentioning
confidence: 99%
“…Касательно схем ХТ, проводимых во II-III триместре беременности, перспективными препаратами оказались антрациклины [58,59]. Приоритетной считается схема FAC (5-фторурацил 500 мг/м 2 на 1 и 4 день внутривенно, доксорубицин 50 мг/м 2 внутривенная 72-часовая инфузия через помпу и циклофосфамид 500 мг/м 2 внутривенно в 1-й день [57,59].…”
Section: химиотерапияunclassified
“…The greatest experience in pregnancy has been with anthracycline and alkylating chemotherapy agents. 392,393 Collected data of chemotherapy exposure in utero indicate that the greatest risk for fetal malformation occurs in the first trimester. 394,395 The risk for fetal malformation in the second and third trimester is approximately 1.3%, which is not different from that for fetuses not exposed to chemotherapy during pregnancy.…”
Section: Special Situationsmentioning
confidence: 99%
“…Recent data from a single institution prospective study indicate that FAC chemotherapy (5-FU 500 mg/m 2 intravenously day 1 and 4, doxorubicin 50 mg/m 2 by intravenous infusion over 72 hours, and cyclophosphamide 500 mg/m 2 intravenously day 1) may be given with relative safety during the second and third trimesters of pregnancy. 393 Ondansetron, lorazepam, and dexamethasone can be used as part of the prechemotherapy antiemetic regimen. In their study, Gwyn and Theriault 382 reported that the median gestational age at delivery was 38 weeks, more than 50% of the patients had vaginal delivery, and no fetal deaths occurred.…”
Section: Special Situationsmentioning
confidence: 99%
See 1 more Smart Citation